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The data presented in this article are related to the research article
entitled “Enhanced Rho-Kinase Activity: Pathophysiological Rele-
vance in Type 2 Diabetes” [1]. Rho-Kinase has attracted a great deal
of interest as a novel therapeutic target in cardiovascular diseases.
These data describe the observed relationship of Rho-Kinase
activity with type 2 diabetic patients. Rho-Kinase activity is
determined by immunoblotting of peripheral blood leukocytes
with the Phospho-Thr853 in the myosin-binding subunit of myosin
light-chain phosphatase. The level of IL-6 is measured using
Enzyme-linked immunosorbent assay.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
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 The stratiﬁcation of participants according to gender adds further insight to these data.
 These data can be used for further studies on the relationship between IL-6 and Rho-Kinase
activity.
 Our data could be useful to characterizing the link between Rho-Kinase and diabetes.1. Data
This article presents ﬁgures describing the variation in Rho-Kinase according to gender and the
relationship of IL-6 and Rho-Kinase activity, in support of the article [1].
The relationship between Rho-kinase activity and gender is presented in Fig. 1.
Distribution of scatter plot diagrams (Fig. 2) show the association between Rho-kinase activity and
IL-6 concentrations.
Seventy-eight volunteers, including 41 type 2 diabetic patients and 37 control subjects, were
participated in this study.2. Experimental design, materials and methods
2.1. Participants
In the current study, 41 patients with type 2 diabetes and 37 controls were recruited from indi-
viduals who admitted the outpatient clinic of Tongji Hospital in Wuhan (Hubei, People's Republic of
China). Type 2 diabetic patients were conﬁrmed by OGTT according to the American Diabetes Asso-
ciation criteria [2], or by a report of the use of medication for type 2 diabetes, or based on a review of
medical records. Patients with type 1 diabetes or gestational diabetes mellitus were excluded on
clinical grounds as described previously [3]. The control subjects were determined to be free of type
2 diabetes by their medical history and OGTT test. This study was approved by the institutional
review board of Tongji Hospital. Experiments were conducted according to the principles expressed
in the Declaration of Helsinki. Written informed consent was obtained from all the participants.
2.2. Measurement of ROCK activity in circulating leukocytes
Rho-kinase activity was assessed by measuring the levels of phosphorylated to total myosin-
binding subunit (MBS) of myosin light-chain phosphatase, a direct downstream target of Rho-kinase,
and by analysis of total Rho-kinase isoforms in circulating leukocytes from venous blood, as pre-
viously reported [4–9]. Fasting venous blood was collected at room temperature in EDTA tubes with
fasudil.
To avoid degradation of target proteins by cellular enzymes, proteins must be prepared rapidly in
the presence of many protease inhibitors. Furthermore, the culture medium is removed rapidly and
completely, and the cells are washed twice with ice-cold phosphate-buffered saline (PBS) before the
addition of protease inhibitors and cell ﬁxatives. Meanwhile, scrape the cell contents and transfer
L. Liu et al. / Data in Brief 9 (2016) 978–982980them to a microcentrifuge tube on ice. After vortexing and centrifuging the samples at 4° for 5 min
over 12,000 rpm, the supernatant is removed and the pellets are collected for Rho-kinase assay. Of
note, proteins are stored at 80° until use.
To avoid the interference by different exposure durations and variable membrane conditions, we
use lipopolysaccharide-pretreated NIH/3T3 cell lysates as a positive control and also to standardize
results between different experiments as suggested [4].
To isolate human leukocytes, all protocols were performed as previously reports [4]. Peripheral
blood leukocytes from fasting venous blood samples were isolated by density gradient centrifugation.
The leukocyte pellet was resuspended in medium 199 and counted by a hematocytometer. Cells were
ﬁxed in 10% trichloroacetic acid and 10 mmol/l dichlorodiphenyltrichloroethane. After centrifugation,
cell pellets were dissolved in lysis buffer. Protein content of supernatants was determined by Bradford
assay. Equal amounts of leukocyte protein extracts were subjected to 6% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and transferred to PVDF membranes. Membranes were incubated
with rabbit anti-phospho-speciﬁc Thr853-MBS polyclonal antibody. Bands were visualized using the
ECL system. Each blot was quantiﬁed by scanning densitometry with the Quantity One software (Bio-
Rad, Hercules, CA).ROCK activity is expressed as the ratio of pMBS in each sample per pMBS in each
positive control divided by MBS in each sample per MBS in each positive control.
2.3. Measurement the serum level of IL-6
The serum level of IL-6 was measured using enzyme immunoassay – the commercially available
IL-6 immunoassay system kit according to the manufacturer's instructions. To determine the con-
centrations of circulating IL-6, a standard curve was created. Samples were assayed in duplicate, and
IL-6 concentrations were derived from a standard curve composed of serial dilutions of puriﬁed
recombinant human IL-6. The assay sensitivity was 0.1 pg/ml. The intra-assay coefﬁcient of variation
(CV) and inter-assay CV were 3–6% and 4–7%, respectively.
2.4. Statistical analysis
The data are expressed as percentages for categorical variables and as mean (standard deviation,
SD) or median (interquartile range, IQR) for the continuous variables depending on their normal
distribution. Shapiro–Wilk tests were used for normal distribution test. Correlations amongMa
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P = 0.20 P = 0.67 
Fig. 1. The relationship between Rho-kinase activity and gender. A: Among female type 2 diabetic patients, leukocyte ROCK
activity were 0.7770.10, which is similar to male type 2 diabetic patients (0.8170.09; P¼0.20. B: In control group, ROCK
activity was not signiﬁcantly different between female and male groups (0.7270.07 vs. 0.7370.09; P¼0.67).
Fig. 2. Correlations of ROCK activity with serum IL-6 concentration in type 2 diabetic patients and control subjects. A: In type
2 diabetic patients, a marginal correlation between the level of IL-6 and ROCK activity has been found (r¼0.29, P¼0.06); B: In
control group, no signiﬁcant correlation between the level of IL-6 and ROCK activity has been found (r¼0.26, P¼0.12).
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compared using the chi-squared test, and Student's t-test or the Mann–Whitney test was used to
compare continuous variables between groups as appropriate. All statistical analyses were performed
with SPSS for Windows, version 15.0 (SPSS Inc., Chicago, IL, USA). Statistical signiﬁcance was deﬁned
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